Padlock Therapeutics is a biotechnology company based in the United States. It was founded in 2014 by Dr. Paul Thompson, Dr.

Tarran Jones, and Dr. Loren Walensky, who are renowned experts in the field of drug discovery and development. The company is headquartered in Cambridge, Massachusetts.

The main focus of Padlock Therapeutics is developing novel therapeutics for autoimmune diseases. The company specializes in the field of protein-arginine deiminase (PAD) inhibitors, which have shown promising potential in treating various autoimmune conditions. The flagship product of Padlock Therapeutics is a PAD inhibitor called PDL-001.

On a global scale, Padlock Therapeutics is actively engaged in collaborations and partnerships to advance its research efforts. In 2015, the company entered into a strategic collaboration with pharmaceutical giant Bristol-Myers Squibb to develop PAD inhibitors for the treatment of rheumatoid arthritis. This partnership provided Padlock Therapeutics with valuable resources and expertise to further its development efforts.

In terms of market position, Padlock Therapeutics is considered a leading player in the field of autoimmune disease therapeutics. The company's innovative approach in targeting PAD enzymes has garnered significant attention from the medical and scientific communities. While specific sales figures are not publicly available, Padlock Therapeutics has been successful in securing significant funding to drive its research and development efforts.

In terms of major events, Padlock Therapeutics was acquired by biopharmaceutical company, Bristol-Myers Squibb, in 2016. This acquisition further validated the potential of Padlock Therapeutics' technology and provided the company with additional resources to advance its pipeline. As of the latest information available, Padlock Therapeutics continues to operate as a subsidiary of Bristol-Myers Squibb.

The company remains focused on developing innovative therapies for autoimmune diseases, with PDL-001 as its lead candidate. The company's progress in clinical development is eagerly awaited, and it continues to be a key player in the field of autoimmune therapeutics